Patents & life sciences

With more than 23 years’ experience of legal practices within the life sciences sector, Scott Farnsworth is recognised as a leading practitioner, highly regarded for his understanding of scientific and technical subject matter, together with his structuring of transactions within the sector.  Having worked as external counsel to large pharma for over 7 years, Scott’s practice within the sector is extensive, attracting instructions from across the United Kingdom and parts of Europe, and has grown entirely from recommendations and referrals.  Scott’s clients include spin-outs from universities and start-ups, charities, pre-clinical and clinical CROs, and SMEs specialising in biotechnology, drug discovery, therapeutics and delivery, medical devices, and the conduct and management of clinical trials.

Scott’s most recent instructions include advice and written materials for pre-clinical R&D, collaborative DMPK/PBPK modelling, early stage drug development with analyses for clinical candidates and hit to lead compounds, integrated drug discovery programmes, MSAs, MTAs and compound evaluations, SPC challenge under European regulations, patent licensing and technology transfers for haemostats in the European, United States and ‘Greater China’ markets with milestone regulatory protocols, LX-2 cell line transfers with cross-licensing, study start-ups of clinical trials, clinical trials for phases I and II (modular) of IMP/IND for HER-2 negative breast cancer in Europe (mCTA) and the United States, equipment transfer and handling for +ve COVID-19 testing, and principles and standards for GLP, GCP and GVP.